Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 163

1.

The neuropsychopharmacology of cannabis: A review of human imaging studies.

Bloomfield MAP, Hindocha C, Green SF, Wall MB, Lees R, Petrilli K, Costello H, Ogunbiyi MO, Bossong MG, Freeman TP.

Pharmacol Ther. 2018 Oct 19. pii: S0163-7258(18)30190-6. doi: 10.1016/j.pharmthera.2018.10.006. [Epub ahead of print] Review.

2.

Survey of Australian psychiatrists' and psychiatry trainees' knowledge about and attitudes towards medicinal cannabinoids.

Jacobs NI, Montebello M, Monds LA, Lintzeris N.

Australas Psychiatry. 2019 Feb;27(1):80-85. doi: 10.1177/1039856218803675. Epub 2018 Oct 9.

PMID:
30298754
3.

Cannabinoids: from pot to lab.

Papaseit E, Pérez-Mañá C, Pérez-Acevedo AP, Hladun O, Torres-Moreno MC, Muga R, Torrens M, Farré M.

Int J Med Sci. 2018 Aug 6;15(12):1286-1295. doi: 10.7150/ijms.27087. eCollection 2018. Review.

4.

Repeated Cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus.

Luján MÁ, Castro-Zavala A, Alegre-Zurano L, Valverde O.

Neuropharmacology. 2018 Dec;143:163-175. doi: 10.1016/j.neuropharm.2018.09.043. Epub 2018 Sep 28.

PMID:
30273593
5.

Unique treatment potential of cannabidiol for the prevention of relapse to drug use.

Weiss F, Gonzalez-Cuevas G.

Neuropsychopharmacology. 2019 Jan;44(1):229. doi: 10.1038/s41386-018-0218-2. No abstract available.

PMID:
30254292
6.

Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework.

Greenwald MK.

Neurobiol Stress. 2018 Aug 11;9:84-104. doi: 10.1016/j.ynstr.2018.08.003. eCollection 2018 Nov. Review.

7.

Cannabinoids determination in bronchoalveolar lavages of cannabis smokers with lung disease.

Rotolo MC, Pellegrini M, Martucci P, Giacobbe R, De Palma A, Pacifici R, Pichini S, Busardò FP, Bisconti M.

Clin Chem Lab Med. 2018 Sep 19. pii: /j/cclm.ahead-of-print/cclm-2018-0426/cclm-2018-0426.xml. doi: 10.1515/cclm-2018-0426. [Epub ahead of print]

PMID:
30231009
8.

Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV).

Mersiades AJ, Tognela A, Haber PS, Stockler M, Lintzeris N, Simes J, McGregor I, Olver I, Allsop DJ, Gedye C, Kirby AC, Morton RL, Fox P, Clarke S, Briscoe K, Aghmesheh M, Wong N, Walsh A, Hahn C, Grimison P.

BMJ Open. 2018 Sep 12;8(9):e020745. doi: 10.1136/bmjopen-2017-020745.

9.

Important Questions About the Impact of Medical Marijuana on People With Serious Mental Illness.

Brunette MF, Borodovsky JT, Myers M, Budney AJ.

Psychiatr Serv. 2018 Sep 6:appips201800210. doi: 10.1176/appi.ps.201800210. [Epub ahead of print]

PMID:
30185124
10.

Cannabis in liver disorders: a friend or a foe?

Goyal H, Rahman MR, Perisetti A, Shah N, Chhabra R.

Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1283-1290. doi: 10.1097/MEG.0000000000001256. Review.

PMID:
30169449
11.

Cannabinoid concentrations in blood and urine after smoking cannabidiol joints.

Meier U, Dussy F, Scheurer E, Mercer-Chalmers-Bender K, Hangartner S.

Forensic Sci Int. 2018 Oct;291:62-67. doi: 10.1016/j.forsciint.2018.08.009. Epub 2018 Aug 11.

PMID:
30149280
12.

A Survey on the Medical Use of Cannabis in Europe: A Position Paper.

Bramness JG, Dom G, Gual A, Mann K, Wurst FM.

Eur Addict Res. 2018;24(4):201-205. doi: 10.1159/000492757. Epub 2018 Aug 22.

PMID:
30134238
13.

Molecular Genetics and New Medication Strategies for Opioid Addiction.

Hurd YL, O'Brien CP.

Am J Psychiatry. 2018 Oct 1;175(10):935-942. doi: 10.1176/appi.ajp.2018.18030352. Epub 2018 Aug 2.

PMID:
30068261
14.

[A brief history of marijuana in the western world].

Leal-Galicia P, Betancourt D, Gonzalez-Gonzalez A, Romo-Parra H.

Rev Neurol. 2018 Aug 16;67(4):133-140. Review. Spanish.

PMID:
30039841
15.

Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community.

Suraev A, Lintzeris N, Stuart J, Kevin RC, Blackburn R, Richards E, Arnold JC, Ireland C, Todd L, Allsop DJ, McGregor IS.

Sci Rep. 2018 Jul 5;8(1):10154. doi: 10.1038/s41598-018-28127-0. Erratum in: Sci Rep. 2018 Aug 2;8(1):11850.

16.

Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol.

Bhardwaj AK, Allsop DJ, Copeland J, McGregor IS, Dunlop A, Shanahan M, Bruno R, Phung N, Montebello M, Sadler C, Gugusheff J, Jackson M, Luksza J, Lintzeris N; Agonist Replacement for Cannabis Dependence (ARCD) study group.

BMC Psychiatry. 2018 May 18;18(1):140. doi: 10.1186/s12888-018-1682-2.

17.

Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal.

Hindocha C, Freeman TP, Grabski M, Stroud JB, Crudgington H, Davies AC, Das RK, Lawn W, Morgan CJA, Curran HV.

Addiction. 2018 May 1. doi: 10.1111/add.14243. [Epub ahead of print]

18.

Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.

Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, Banks SL, Stinchcomb AL, Weiss F.

Neuropsychopharmacology. 2018 Sep;43(10):2036-2045. doi: 10.1038/s41386-018-0050-8. Epub 2018 Mar 22.

19.

A naturalistic examination of the perceived effects of cannabis on negative affect.

Cuttler C, Spradlin A, McLaughlin RJ.

J Affect Disord. 2018 Aug 1;235:198-205. doi: 10.1016/j.jad.2018.04.054. Epub 2018 Apr 6.

20.

Police probe of Brazilian marijuana researcher sparks protests.

Angelo C.

Nature. 2018 Mar 15;555(7696):296. doi: 10.1038/d41586-018-02842-0. No abstract available.

PMID:
29542710

Supplemental Content

Loading ...
Support Center